Eli Lilly & Co. reported a significant increase in its fourth-quarter earnings for 2024, with net income doubling to $4.41 billion from $2.2 billion the previous year. The company's adjusted earnings per share (EPS) reached $5.32, surpassing the consensus estimate of $5.06. Revenue for the quarter rose 45% to $13.53 billion, slightly above the expected $13.45 billion. The growth was primarily driven by strong sales of its diabetes treatment Mounjaro, which generated $3.53 billion in revenue, and obesity drug Zepbound, which brought in $1.91 billion. Despite these successes, sales of both drugs fell short of analyst expectations. Eli Lilly also provided a 2025 outlook, forecasting adjusted EPS to be between $22.50 and $24.00, compared to the consensus estimate of $23.17, and revenue to be between $58 billion and $61 billion, slightly below the market's expectation of $59.41 billion. The company's shares rose following the earnings announcement, reflecting investor confidence in its future growth prospects.